P&G Asks FDA To Make Prilosec The Standard For OTC PPI Claims
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble is asking FDA to develop class labeling for OTC proton pump inhibitors that would effectively preclude all products in the category from claiming greater efficacy than P&G's Prilosec OTC